UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Journal of clinical oncology, 2011-07, Vol.29 (21), p.2866-2875

2011

Volltextzugriff (PDF)

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

Journal of clinical oncology, 2010-02, Vol.28 (5), p.744-752

2010

Volltextzugriff (PDF)

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples

Journal of experimental & clinical cancer research, 2010-10, Vol.29 (1), p.132-132, Article 132

2010

Volltextzugriff (PDF)

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

Journal of clinical oncology, 2008-09, Vol.26 (26), p.4253-4260

2008

Volltextzugriff (PDF)

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

Clinical cancer research, 2010-02, Vol.16 (4), p.1159-1169

2010

Volltextzugriff (PDF)

Integration of Laser Scanning and Three-dimensional Models in the Legal Process Following an Industrial Accident

Safety and Health at Work, 2017, 8(3), , pp.306-314

2017

Volltextzugriff (PDF)

Integration of Laser Scanning and Three-dimensional Models in the Legal Process Following an Industrial Accident

Safety and health at work, 2017-09, Vol.8 (3), p.306-314

2017

Volltextzugriff (PDF)

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

Journal of clinical pathology, 2013-02, Vol.66 (2), p.79-89

2013

Volltextzugriff (PDF)

Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

Journal of clinical oncology, 2009-04, Vol.27 (11), p.1864-1871

2009

Volltextzugriff (PDF)

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

Journal of clinical oncology, 2009-04, Vol.27 (11), p.1864-1871

2009

Volltextzugriff (PDF)

A service evaluation of a psychological skills group for people diagnosed with multiple sclerosis

Clinical psychology forum (Leicester, England : 2005), 2016-12 (288), p.28

2016

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Immunohistochemistry : Comparison of Antibodies and Cutoff Points to Predict Benefit From Gefitinib in a Phase 3 Placebo-Controlled Study in Advanced Nonsmall-Cell Lung Cancer

Cancer, 2008-03, Vol.112 (5), p.1114-1121

2008

Volltextzugriff (PDF)

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

Anti-cancer drugs, 2009-11, Vol.20 (10), p.856-866

2009

Volltextzugriff (PDF)

Abstract 912: Targeting HER family signaling in low HER2-expressing breast cancer: activity of the selective and equipotent EGFR, HER2 and HER3 signaling inhibitor, AZD8931, in models of low HER2-expressing disease

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.912-912

2013

Volltextzugriff (PDF)

Recent developments related to the EGFR as a target for cancer chemotherapy

Current opinion in pharmacology, 2005-08, Vol.5 (4), p.343-349

2005

Volltextzugriff (PDF)

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer

International journal of oncology, 2011-07, Vol.39 (1), p.271-278

2011

Volltextzugriff (PDF)

Epidermal growth factor receptor immunohistochemistry

Cancer, 2008-03, Vol.112 (5), p.1114-1121

2008

Volltextzugriff (PDF)

Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib

Clinical and translational science, 2009-06, Vol.2 (3), p.183-192

2009

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(18)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

Integration of Laser Scanning and Three-dimensional Models in the Legal Process Following an Industrial Accident

Integration of Laser Scanning and Three-dimensional Models in the Legal Process Following an Industrial Accident

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

A service evaluation of a psychological skills group for people diagnosed with multiple sclerosis

Epidermal Growth Factor Receptor Immunohistochemistry : Comparison of Antibodies and Cutoff Points to Predict Benefit From Gefitinib in a Phase 3 Placebo-Controlled Study in Advanced Nonsmall-Cell Lung Cancer

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

Abstract 912: Targeting HER family signaling in low HER2-expressing breast cancer: activity of the selective and equipotent EGFR, HER2 and HER3 signaling inhibitor, AZD8931, in models of low HER2-expressing disease

Recent developments related to the EGFR as a target for cancer chemotherapy

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer

Epidermal growth factor receptor immunohistochemistry

Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib

Suchergebnisse filtern